Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Amanda R. Dancsok"'
Autor:
Amanda R. Dancsok, Dongxia Gao, Anna F. Lee, Sonja Eriksson Steigen, Jean-Yves Blay, David M. Thomas, Robert G. Maki, Torsten O. Nielsen, Elizabeth G. Demicco
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Early trials for immune checkpoint inhibitors in sarcomas have delivered mixed results, and efforts to improve outcomes now look to combinatorial strategies with novel immunotherapeutics, including some that target macrophages. To enhance our underst
Externí odkaz:
https://doaj.org/article/9e799c27028b46f5812c8bcc54b10c57
Autor:
Dongxia Gao, Anna F. Lee, David Thomas, Sonja E. Steigen, Jean-Yves Blay, Robert G. Maki, Torsten O. Nielsen, Elizabeth G Demicco, Amanda R. Dancsok
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol 9, Iss 1 (2020)
Early trials for immune checkpoint inhibitors in sarcomas have delivered mixed results, and efforts to improve outcomes now look to combinatorial strategies with novel immunotherapeutics, including some that target macrophages. To enhance our underst
Publikováno v:
Current oncology reports. 21(1)
This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors. IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis
Autor:
Jean-Yves Blay, Nokitaka Setsu, Elizabeth G Demicco, Dongxia Gao, Torsten O. Nielsen, Amanda R. Dancsok, Robert G. Maki, David Thomas
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 32(12)
Despite advances in our understanding of the underlying molecular drivers of sarcomas, few treatments are available with proven benefit for advanced metastatic sarcomas. Immunotherapy has value in this setting for some types of cancers, but sarcomas,
Publikováno v:
Oncotarget
// Amanda R. Dancsok 1 , Karama Asleh-Aburaya 1 and Torsten O. Nielsen 1,2 1 Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada 2 Sarcoma Disease Site Committee, Canadian Cancer Trials Group Correspondence to: Am
Publikováno v:
Seminars in cancer biology. 52(Pt 2)
The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor immune responses. These agents led to unprecedented results in patients with
Autor:
Katerina Hatzi, Francisco Sanchez-Vega, Darjus F. Tschaharganeh, Christopher R. Vakoc, Jae Seok Roe, Aimée N. Laporte, Ana Banito, Chi-Chao Chen, Nilgun Tasdemir, Torsten O. Nielsen, Scott W. Lowe, Marc Ladanyi, Mario R. Capecchi, Xiang Li, Kevin B. Jones, Chun-Hao Huang, Rohit Chandwani, Amanda R. Dancsok, Nikolaus Schultz
Publikováno v:
Cancer Cell. 33:527-541.e8
Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX (SSX1 or SSX2) transcriptional repressor. Using functional genomics, we identify KD
Autor:
Jean-Yves Blay, Torsten O. Nielsen, David Thomas, Elizabeth G. Demicco, Robert G. Maki, Amanda R. Dancsok
Publikováno v:
Clinical Cancer Research. 24:B32-B32
Recent clinical trials of immune checkpoint inhibitors have raised hopes for sarcoma therapy, but they have not taken into account the variability of the immune microenvironment in their design or interpretation. Here, we present a comprehensive anal